Vitamin E attenuates reserpine-induced oral dyskinesia and striatal oxidized glutathione/reduced glutathione ratio (GSSG/GSH) enhancement in rats

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 27, Issue 1, 2003, Pages 109-114

  Abílio, Vanessa C ^a   Araujo, Carlos C S ^a   Bergamo, Marcelo ^a   Calvente, Patricia R V ^a   D'Almeida, Vânia ^a   Ribeiro, Rosana De A ^a   Frussa Filho, Roberto ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Oxidative stress; Rat; Reserpine; Tardive dyskinesia; Tongue protrusion; Vitamin E

Indexed keywords

ALPHA TOCOPHEROL; GLUTATHIONE; GLUTATHIONE DISULFIDE; RESERPINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR; CONTROLLED STUDY; CORPUS STRIATUM; DRUG EFFECT; DYSKINESIA; MALE; NONHUMAN; OXIDATIVE STRESS; QUANTITATIVE ASSAY; RAT;

EID: 0037304463     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0278-5846(02)00340-8     Document Type: Article

References (42)

1. Abílio V.C., Vera J.A.R. Jr., Ferreira L.S.M., Duarte C.R.M., Carvalho R.C., Grassl C., Martins C.R., Torres-Leite D., Bignotto M., Tufik S., Ribeiro R. de A., Frussa-Filho R. Effects of melatonin on orofacial movements in rats. Psychopharmacology. 161:2002;340-347.
2. Andreassen O.E., Jørgensen H.A. Neurotoxicity associated with neuroleptic-induced oral dyskinesias in rats. Prog. Neurobiol. 61:2000;525-541.
3. Bains J.S., Shaw C.A. Neurodegenerative disorders in humans: the role of glutathione in oxidative stress-mediated neuronal death. Brain Res. Rev. 25:1997;335-358.
4. Barak Y., Swartz M., Shamir E., Stein D., Weizman A. Vitamin E (alpha-tocopherol) in the treatment of tardive dyskinesia: a statistical meta-analysis. Ann. Clin. Psychiatry. 10:1998;101-105.
5. Beal M.F., Ferrante R.J., Henshaw R., Matthews R.T., Chan P.H., Kowall N.W., Epstein C.J., Schulz J.B. 3-Nitropropionic acid neurotoxicity is attenuated in cooper/zinc superoxide dismutase transgenic mice. J. Neurochem. 65:1995;919-922.
6. Behl C., Rupprecht R., Skutella T., Holsboer F. Haloperidol-induced cell death-mechanism and protection with vitamin E in vitro. NeuroReport. 7:1995;360-364.
7. Behl C., Lezoulach F., Widmann M., Rupprecht R., Holsboer F. Oxidative stress-resistant cells are protected against haloperidol toxicity. Brain Res. 717:1996;193-195.
8. Benzi G., Moretti A. Age- and peroxidative stress-related modifications of the cerebral enzymatic activities linked to mitochondria and the glutathione system. Free Radic. Biol. Med. 19:1995;77-101.
9. Bergamo M., Abilio V.C., Queiroz C.M.T., Barbosa H.M. Jr., Abdanur L.R.A., Frussa-Filho R. Effects of age on a new animal model of tardive dyskinesia. Neurobiol. Aging. 18:1997;623-629.
10. Caligiuri M.P., Lohr J.B., Bracha H.S., Jeste D.V. Clinical and instrumental assessment of neuroleptic-induced parkinsonism in patients with tardive dyskinesia. Biol. Psychiatry. 29:1991;138-148.
11. Calvente P.R.V., Araujo C.C.S., Bergamo M., Abílio V.C., D'Almeida V., Ribeiro R. de A., Frussa-Filho R. The mitochondrial toxin 3-nitropropionic acid aggravates reserpine-induced oral dyskinesia in rats. Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 26:2002;1-5.
12. Casey D.E. Tardive dyskinesia - pathophysiology. Bloom F.E., Kupfer D.J. Psychopharmacology: the Fourth Generation of Progress. 1995;1497-1502 Raven Press, New York.
13. Eranti V.S., Gangadhar B.N., Janakiramaiah N. Haloperidol-induced extrapyramidal reaction: lack of protective effect by vitamin E. Psychopharmacology. 140:1998;418-420.
14. Fighera M.R., Queiroz C.M., Stracke M.P., Brauer M.C.N., Gonzalez-Rodriguez L.L., Frussa-Filho R., Wajner M., Mello C.F. Ascorbic acid an α-tocopherol attenuate methylmalonic acid-induced convulsions. Neuropharmacology. 10:1999;2039-2043.
15. Frussa-Filho R., Palermo-Neto J. Effects of single and long-term of metoclopramide administration on open-field and stereotyped behavior in rats. Eur. J. Pharmacol. 149:1988;323-329.
16. Gardos G., Cole J.O. The treatment of tardive dyskinesias. Bloom F.E., Kupfer D.J. Psychopharmacology: The Fourth Generation of Progress. 1995;1503-1511 Raven Press, New York.
17. Gattaz W.F., Emrich A., Behrens S. Vitamin E attenuates the development of haloperidol-induced dopaminergic hypersensitivity in rats: possible implications for tardive dyskinesia. J. Neural Transm. 92:1993;197-201.
18. Gerlach J., Casey D.E. Tardive dyskinesia. Acta Psychiatry Scan. 77:1988;369.
19. Kane J.M., Woerner M., Lieberman J. Tardive dyskinesia: prevalence, incidence and risk factors. Casey D.E., Chase T.N., Christensen A.V., Gerlach J. Dyskinesia: Research and Treatment. 1985;72-78 Springer-Verlag, Berlin.
20. Kleeb S.R., Rizzo M.S., Dagli M.L.Z., Frussa-Filho R. Haloperidol increases spreading and nitric oxide production in macrophages from tumor-bearing mice: a possible mechanism for its antitumoral effect. Int. J. Immunopharmacol. 21:1999;575-580.
21. Levy A.D., See R.E., Levin E.D., Ellison G.D. Neuroleptic-induced oral movements in rats: methodological issues. Life Sci. 41:1987;1499-1506.
22. Lohr J.B. Oxygen free radicals and neuropsychiatric illness. Arch. Gen. Psychiatry. 48:1991;1097-1106.
23. Lohr J.B., Kuczenski R., Bracha H.S., Moir M., Jeste D.V. Increased indices of free radical activity in the cerebrospinal fluid of patients with tardive dyskinesia. Biol. Psychiatry. 28:1990;535-539.
24. Maulik N., Das D.K., Gogineni M., Cordis G.A., Avrova N., Denisova N. Reduction of myocardial ischemic reperfusion injury by sialylated glycosphingolipids, gangliosides. J. Cardiovasc. Pharmacol. 22:1993;74-81.
25. Menzaghi F., Whelan K.T., Risbrough V.B., Rao T.S., Lloyd G.K. Interactions between a novel cholinergic ion channel agonist, SIB-1765F and L-DOPA in the reserpine model of Parkinson's disease in rats. J. Pharmacol. Exp. Ther. 280:1997;391-401.
26. Neisewander J.L., Lucki I., McGonigle P. Neurochemical changes associated with the persistence of spontaneous oral dyskinesia in rats following chronic reserpine treatment. Brain Res. 558:1991;27-35.
27. Neisewander J.L., Lucki I., McGonigle P. Behavioral and neurochemical effects of chronic administration of reserpine and SKF-38393 in rats. J. Pharmacol. Exp. Ther. 257:1991;850-860.
28. Neisewander J.L., Castaneda E., Davis D.A. Dose-dependent differences in the development of reserpine-induced oral dyskinesia in rats: support for a model of tardive dyskinesia. Psychopharmacology. 116:1994;79-84.
29. Neisewander J.L., Castaneda E., Davis D.A., Elson H.J., Sussman A.N. Effects of amphetamine and 6-hydroxydopamine lesions on reserpine-induced oral dyskinesia. Eur. J. Pharmacol. 305:1996;13-21.
30. Owens D.G.C. Tardive dyskinesia. Owens D.G.C. A Guide to the Extrapyramidal Side-Effects of Antipsychotic Drugs. 1999;166-226 Cambridge Press, Cambridge.
31. Queiroz C.M.T., Frussa-Filho R. Effects of buspirone on an animal model of tardive dyskinesia. Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 23:1999;1405-1418.
32. Queiroz C.M.T., Piovezan R.D., Frussa-Filho R. Reserpine does not induce orofacial dyskinesia in spontaneously hypertensive rats. Eur. J. Pharmacol. 356:1998;105-108.
33. Reiter R.J. Oxidative damage in the central nervous system: protection by melatonin. Prog. Neurobiol. 56:1998;359-384.
34. Sakai K., Gao X.-M., Tamminga C.A. Scopolamine fails to diminish chronic haloperidol-induced purposeless chewing in rats. Psychopharmacology. 153:2001;191-195.
35. Sussman A.N., Tran-Nguyen L.T.L., Neisewander J.L. Acute reserpine administration elicits long-term spontaneous oral dyskinesia. Eur. J. Pharmacol. 337:1997;157-160.
36. Takeuchi H., Ishigooka J., Kobayashi K., Watanabe S., Miura S. Study on the suitability of a rat model for tardive dyskinesia and the preventive effects of various drugs. Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 22:1998;679-691.
37. Tietze F. Enzymic method for quantitative determination of nanogram amounts of total and oxidized glutathione: applications to mammalian blood and other tissues. Anal. Biochem. 27:1969;502-522.
38. Toborek M., Henning B. Fatty acid-mediated effects on the glutathione redox cycle in cultured endothelial cells. Am. J. Clin. Nutr. 59:1994;60-65.
39. Uhrbrand L., Faurbye A. Reversible and irreversible dyskinesia after treatment with perphenazine, chlorpromazide, reserpine and electroconvulsive therapy. Psychopharmacology. 1:1960;408-418.
40. Vital M.A.B.F., Frussa-Filho R., Palerrno-Neto J. Effects of monosialoganglioside on a new model of tardive dyskinesia. Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 21:1997;1169-1179.
41. Waddington J.L. Spontaneous orofacial movements induced in rodents by very long-term neuroleptic drug administration: phenomenology, pathophysiology and putative relationship to tardive dyskinesia. Psychopharmacology. 101:1990;431-447.
42. Wolfarth S., Ossowska K. Can supersensitivity of rodents to dopamine be regarded as a model of tardive dyskinesia? Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 13:1989;789-840.